chemotherapy – Page 15 – Oral Cancer News

Exercise helps cancer patients

Source: www.dailyrx.com Author: staff A small trial shows that rehabilitation therapy for head and neck cancer patients clearly improves their ability to swallow faster, something that's often damaged with the cancer treatment. Intense treatment for cancers of the head and neck often involves both chemotherapy and radiation. With many important muscles involved in the region, preventing the areas targeted by radiation from weakening can be avoided with swallowing exercises. The study compared a control group given no swallowing exercises to another group given the series of targeted rehabilitation therapy. It took nine months for the two groups to have equivalent ability, highlighting the importance of preserving muscle function prior to cancer treatment. Importantly, rehabilitation after cancer treatment can prevent some of the worst side effects, and allows patients to get back to their normal day to day life. The initial damage from cancer treatment was extensive, as both groups had equal ability immediately after cancer therapy. Yet the muscle function rebounded quickly in the rehabilitation group, as results at 3 and 6 months after treatment were improved as a result of the swallowing exercises. The group given exercises also rated themselves as more comfortable eating in public, an important qualifier in showing how well the exercises worked. "With improvements in swallowing function from post-treatment exercises, interest in the use of prophylactic swallowing exercises to prevent or minimize post-CRT swallowing dysfunction has grown" the authors write as background in the study. "Indeed, some cancer treatment centers recommend prophylactic swallowing exercises for [...]

Oral Cancer Foundation News Team - A2012-04-30T12:28:50-07:00April, 2012|Oral Cancer News|

Study: Oral cancers take financial toll

Source: Dr.Biscuspid.com April 26, 2012 -- The cost of treating individuals with oral, orapharyngeal, and salivary gland cancers is significant, particularly for patients who undergo all three forms of treatment, according to a new study by Delta Dental of Michigan's Research and Data Institute. And for many that is only the beginning of the financial impact of the disease. The project, which involved Thomson Reuters, Delta Dental of Wisconsin, Vanderbilt University, and the University of Illinois at Chicago College of Dentistry, began in March 2010. It is the first retrospective data analysis of a large number of head and neck cancer patients in the U.S. analyzing direct and indirect costs and comparing those costs to a matched comparison group, according to the authors (Head Neck Onc, April 26, 2012). Using data from the 2004-2008 Thomson Reuters MarketScan Databases: Commercial Claims and Encounters Database, Medicare Supplemental and Coordination of Benefits Database, Medicaid Multi-State Database, and the Health Productivity and Management Database, the researchers retrospectively analyzed claims data of 6,812 OC/OP/SG patients with employer-sponsored health insurance, Medicare, or Medicaid benefits. They found that, on average, total annual healthcare spending during the year following diagnosis was $79,151, compared with $7,419 in a group comprising similar patients without these cancers. They also found that the average cost of care almost doubled when patients received all three types of treatment: surgery, radiation, and chemotherapy. Healthcare costs were higher for oral cancer patients with commercial insurance ($71,732, n = 3,918), Medicare ($35,890, n = 2,303), and [...]

Charlotte Parker2012-04-27T10:16:48-07:00April, 2012|OCF In The News, Oral Cancer News|

Cold comfort in quest for cancer cure

Source: www.theage.com.au Author: Rachel Browne Can the common cold cure cancer? It's a tempting idea and one on the cutting edge of a new medical research field called oncolytic virotherapy. Common viruses have become the latest weapon against cancer with a small Australian biotechnology group one of the leaders in the field. The idea has been around for some time. The classical Greek physician Hippocrates is often credited with the saying, "Give me the power to create a fever, and I shall cure any disease." More than 2500 years later, scientists, including a team from the University of Newcastle, are proving that the theory has merit. Not only did the classical Greeks make the observation, but there have been some instances of cancer patients entering spontaneous remission after exposure to certain viruses in the past century. There is the case of the eight-year-old African boy diagnosed with Burkitt's lymphoma at a Ugandan health clinic. He was exposed to the measles virus and over the next few weeks his tumour regressed completely and he entered remission. An incident documented by the British medical journal <em>The Lancet</em> in 1971 described the example of a Hungarian chicken farmer who had advanced colorectal cancer. An outbreak of the avian virus Newcastle disease hit the farm, the man became infected and went into remission. But only relatively recently have scientists clinically examined the interaction between viruses and cancers in the growing area of oncolytic virotherapy. Associate Professor Darren Shafren of the University of Newcastle has [...]

Oral Cancer Foundation News Team - A2012-04-22T08:56:20-07:00April, 2012|Oral Cancer News|

When life hands you cancer, make cancer-ade: via lemonade stand, 6yo boy raises $10K for dad’s chemo

Source: Boingboing.net A story making the rounds this week: Drew Cox, a 6 year old boy in Texas, "decided to sell lemonade to help his father with medical bills." His dad, Randy Cox, has a rare form of metastatic cancer, diagnosed a few months ago. The family says Drew's lemonade stand earned more than $10,000. They have an online fundraising site here, where they're trying to raise more. I am currently undergoing chemotherapy for breast cancer, diagnosed about four months ago. When I saw various versions of this story popping up on news sites, several thoughts came to mind. First, hooray for this child. I hope his dad gets the treatment he needs, that the treatment is successful, and that the family doesn't go into debt or have to forego treatment for lack of funds. But second: this is a disgrace. I hate it when stories like this are flogged in media as "feel-good" stories. This story should make America feel ashamed, not feel good. Seriously? A working father gets cancer, and the family has to rely on charity, and a lemonade stand manned by their 6 year old son, to obtain life-sustaining medical treatment? It's not the first such lemonade/chemo-money story to make the rounds in the media, wrapped up in feel-good. When life hands you cancer, the news narrative seems to be, just make cancer-ade! Well, I have cancer. I have insurance. I still pay what is for me a huge out-of-pocket sum, even after my insurance, for [...]

Charlotte Parker2012-04-18T14:54:16-07:00April, 2012|Oral Cancer News|

Cancer medicine is stuck in the past

Source: www.technologyreview.com Author: Susan Young Pathologists and doctors are using a 19th century definition of cancer to diagnose the disease, which leads to unnecessary treatment in some cases, according to Otis Brawley, Chief Medical Officer of the American Cancer Society. Speaking on Thursday at the 2012 TEDMED conference, Brawley called for a 21st century approach to cancer diagnosis; and a modern, genomics-based appreciation of cancer so that patients don't undergo surgeries and chemotherapy for tumors that pose little threat. Pathologists still use drawings made in 1840 to determine whether the cells in a biopsy are cancerous or not, said Brawley. When a lump is deemed to be cancerous, surgery often follows. But as many as 25% of breast cancers and, by some estimates, 60% of prostate cancers could be left untreated and merely monitored, he said. Brawley said the medical community needs to use genomic sequencing to identify the genetic signals of those cancers that doctors need to watch and those that need to be treated. This could be achieved by sequencing tumors from different cancer patients and looking for a genetic "profile" that is associated with dangerous, stable, or benign cancers.

Oral Cancer Foundation News Team - A2012-04-17T05:13:15-07:00April, 2012|Oral Cancer News|

The Gardasil Problem: How The U.S. Lost Faith In A Promising Vaccine

Source: Forbes Magazine, written by Matthew Herper Neal Fowler, 50, the chief executive officer of a tiny biotech called Liquidia, was assuming a position common to road-warrior entrepreneurs: leaning his elbows on the seat-back tray in an airplane so he could gaze at the screen of his laptop. That’s when he felt the lump in his neck. Fowler, a pharmacist, figured his lymph node was swollen by a recent cold, but the oncologist seated next to him—his chairman of the board—thought they’d better keep an eye on it. The chairman was right. Over the next week the lymph node got bigger and harder. It was not sore to the touch, as happens during a cold. Fowler went to the doctor, then a specialist who knew exactly what he was seeing: a new form of throat cancer that ear, nose and throat specialists across the U.S. now say dominates their practices. Some 8,000 of these tonsil tumors turn up each year nationwide, courtesy of strain 16 of the human papilloma virus—the same sexually transmitted virus that causes cervical cancer. Usually transmitted when men perform oral sex on women, it can also spread through other forms of contact, perhaps even just kissing. His prognosis was good—80% of those with this new tumor survive. His status as a drug industry veteran and chief executive of a biotechnology company didn’t hurt, either. He went from diagnosis to having the primary tumor removed from his tonsil in just a day. His first team of doctors [...]

Charlotte Parker2012-04-05T21:25:34-07:00April, 2012|Oral Cancer News|

Head And Neck Cancer Chemotherapy Efficacy Boosted By Human Virus

Source: MedicalNewsToday.com Preliminary data from a trial published in Clinical Cancer Research shows that a harmless human virus that occurs naturally could potentially boost the effects of two standard chemotherapy drugs in some cancer patients. Oncolytics Biotech Inc. developed a new drug, RT3D that will be marketed under the trade name of Reolysin. The drug is based on a virus, i.e. reovirus type 3 Dearing that is commonly found in the respiratory and gastrointestinal tracts of almost every adult without causing any symptoms. RT3D can grow and kill certain types of cancer cells, but it does not grow in normal cells. Earlier trials whereby patients were injected with only the virus displayed limited effectiveness, however, the team discovered that the effects of platin and taxane-based chemotherapy on tumor cells seemed to be magnified by RT3D. Dr Kevin Harrington and his team decided to start a clinical trial in which they examined intravenous RT3D in combination with chemotherapeutics carboplatin and paclitaxel in 31 patients with advanced cancers that had become unresponsive to standard treatments. They conducted an initial Phase I study in patients with a variety of advanced cancers, which demonstrated that the drug combination was safe, with generally mild side effects that were consistent with chemotherapy alone. The best responses were observed in patients with head and neck cancers, including tumors of the nasal cavity, eye, tongue, gums, lip, cheeks, voice box and esophagus. Worldwide, each year about 650,000 people are diagnosed with squamous cell cancer of the head and [...]

Charlotte Parker2012-04-03T10:50:41-07:00April, 2012|Oral Cancer News|

April: Oral Cancer Awareness Month

Source: Aspen Dental April is Oral Cancer Awareness Month. According to Brian Hill, founder and executive director of the Oral Cancer Foundation, as many as 40,000 people in the United States will be told they have oral or pharyngeal cancer in 2012. Some of them may be sitting in your dental chair today. With one person dying of oral cancer every hour of every day, and more than 50% of those diagnosed not living more than 5 years, this is a reminder to screen every patient yourself, and encourage your dental hygiene staff to do the same. The Statistics About 100 people are diagnosed with oral cancer every day in the United States. Few people are aware that the death rate for oral cancer is higher than for many other types of cancers, which is because oral cancer often is not discovered until it has reached later stages. This is particularly true for human papilloma virus number 16 (HPV16)-related oral cancer, which occurs most frequently in the posterior areas of the mouth—at the base of the tongue, around the tonsils, and in the oropharynx—where it’s harder to spot without a very thorough exam. To further complicate things, HPV16-related cancer does not always present the tell-tale physical characteristics, including lesions, that are easily distinguished from healthy oral tissues. This is not good news, because HPV16 has reached epidemic levels in the United States: of the 37,000 incidences of oral cancer, about 20,000 (up to 60%) can be linked to HPV, according [...]

Charlotte Parker2012-04-02T09:47:20-07:00April, 2012|OCF In The News, Oral Cancer News|

Nobel Laureate Makes Strong Case for Vaccinating Young Males Against HPV to Prevent Cervical Cancer in Females

Source: Therapeutics Daily AUSTIN, Texas, March 26, 2012 /PRNewswire-USNewswire/ -- Nobel Prize winner Harald zur Hausen called for vaccinating both young males and females for human papilloma virus (HPV) in an achievable quest to eradicate cervical cancer, which is the second leading type of women's cancer worldwide. Zur Hausen made his remarks at a gathering of more than 1,600 members of the Society of Gynecologic Oncology during its 43rd Annual Meeting on Women's Cancer® in Austin. "If we wish to eradicate these types of infections – then theoretically we can do it," zur Hausen said. "And if we wish to achieve this (eradication of HPV) in a foreseeable period of time, then we should vaccinate both genders globally." He pointed out that educational, cultural and religious barriers contribute to the lack of knowledge or willingness to address or discuss the subject by public health officials, teachers, parents and even some physicians. Zur Hausen also said that if society were to vaccinate just one gender to prevent the spread of cervical-cancer causing HPV, it would be more effective to vaccinate just males, highlighting the potential medical value of male HPV vaccinations. Zur Hausen also noted that research shows that early fears of the side effects of the HPV vaccine were overblown, and Australian research shows that there is about one adverse reaction in 100,000 vaccinations, which confirms the safe nature of the vaccine. Keynote speaker for this year's Annual Meeting on Women's Cancer, Harald zur Hausen was awarded the Nobel Prize [...]

Charlotte Parker2012-03-27T09:45:37-07:00March, 2012|Oral Cancer News|

Grant Achatz Drops Malpractice Suits After Four-Year Battle

Source: Crain's Chicago Business Renowned chef Grant Achatz, whose successful battle with tongue cancer added an unusual twist to his story, has dropped his medical malpractice lawsuits filed against Chicago dentists. Mr. Achatz sued two dentists and their practices in April 2008 in Cook County Circuit Court for negligence. He claimed neither took the steps necessary to diagnose his cancer. He sought damages in excess of $50,000 plus court costs. The last of the suits, one filed against Dr. Loveline Dulay and her Wilmette practice, was dismissed Wednesday, according to another defendant's attorney. The medical malpractice trial had already started with jury selection under way, the attorney said. Mr. Achatz's attorney, Chuck Hornewer of Phillips Law Offices of Chicago, declined to comment. Mr. Achatz and his business partner Nick Kokonas opened Alinea in 2005. While it was accumulating accolades from around the country (and eventually from around the world), Mr. Achatz noticed a painful lesion on his tongue. In November 2005 he visited Dr. Dulay, who did not order a biopsy, a decision that Mr. Achatz said was negligent, according to his original complaint. In July 2006, he visited Dr. Michelle Schwartz at Bucktown Wicker Park Dental Associates, who also did not order a biopsy. Mr. Achatz believed she was also negligent, according to the original complaint. By 2007, he was diagnosed with stage 4 tongue cancer, and doctors found the cancer metastasized to his neck. He took part in a University of Chicago clinical trial that used radiation and [...]

Charlotte Parker2012-03-22T15:24:48-07:00March, 2012|Oral Cancer News|